CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

被引：0
|
作者：
Martinez-Verbo, Laura [1 ]
Villanueva, Lorea [1 ]
Llinas-Arias, Pere [1 ]
Garcia-Prieto, Carlos Antonio [1 ,2 ]
Pineyro, David [1 ]
Oliver-Caldes, Aina [3 ,4 ]
Garcia-Ortiz, Almudena [5 ]
Valeri, Antonio [6 ]
Fernandez de Larrea, Carlos [7 ,8 ]
Martinez-Lopez, Joaquin [9 ]
Ferrer, Gerardo [1 ,10 ,11 ]
Esteller, Manel [1 ,11 ,12 ,13 ]
机构：
[1] Josep Carreras Leukaemia Res Inst, Epigenet, Badalona, Spain
[2] Barcelona Supercomp Ctr, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
[5] Hosp Univ 12 Octubre Ctr Nacl Invest Oncol, Haematol Malignancies Clin Res unit, Madrid, Spain
[6] Univ Complutense Madrid, Hosp Univ 12 Octubre, Dept Hematol, Spanish Natl Canc Res Ctr CNIO, Madrid, Spain
[7] Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
[8] Hosp Clin Barcelona, Barcelona, Spain
[9] Hosp Univ 12 Octubre, CIBER ONC CB16 12 00369, CNIO, Madrid, Spain
[10] Feinstein Inst Med Res, Manhasset, NY USA
[11] Ctr Invest Biomed Red Canc, Madrid, Spain
[12] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain
[13] Univ Barcelona, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179313
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
651
引用
收藏
页数：4
相关论文
共 11 条
  • [1] Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
    Fionda, Cinzia
    Abruzzese, Maria Pia
    Zingoni, Alessandra
    Soriani, Alessandra
    Ricci, Biancamaria
    Molfetta, Rosa
    Paolini, Rossella
    Santoni, Angela
    Cippitelli, Marco
    BMC CANCER, 2015, 15
  • [2] Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
    Cinzia Fionda
    Maria Pia Abruzzese
    Alessandra Zingoni
    Alessandra Soriani
    Biancamaria Ricci
    Rosa Molfetta
    Rossella Paolini
    Angela Santoni
    Marco Cippitelli
    BMC Cancer, 15
  • [3] Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression
    Ishibashi, Mariko
    Kinoshita, Ryosuke
    Inokuchi, Koiti
    Handa, Hiroshi
    Sasaki, Makoto
    Komatsu, Norio
    Imai, Yoichi
    Hiroike, Norina
    Tanaka, Junji
    Tanosaki, Sakae
    Ito, Shigeki
    Sunakawa, Mika
    Asayama, Toshio
    Kuribayashi-hamada, Yasuko
    Morita, Rimpei
    Tamura, Hideto
    BLOOD, 2019, 134
  • [4] Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy
    Ray, Arghya
    Mo, Clifton C.
    DU, Ting
    Olguin, Arturo
    Chen, Janice
    Brooks, Christopher L.
    Mughal, Tariq I.
    Richardson, Paul G.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2021, 138
  • [5] Quantitative seroproteomics analysis of Multiple Myeloma patients treated with Tagraxofusp, a novel CD123-directed targeted therapy, identifies novel cytokine-mediated mechanism of action
    Ray, Arghya
    Du, Ting
    Mo, Clifton
    Olguin, Arturo
    Chen, Janice
    Brooks, Christopher
    Mughal, Tariq
    Richardson, Paul G.
    Chauhan, Dharminder
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S86 - S86
  • [6] Immunotherapy in Multiple Myeloma: Boom or Bust? Investigating Oligoclonal Banding and Survival in Multiple Myeloma Patients Receiving Anti CD3-CD28 Co-Stimulated and Engineered Autologous T cells after Autologous Stem Cell Transplant
    Ioffe, Dina
    Goloubeva, Olga
    Rapoport, Aaron
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E162 - E163
  • [7] Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma
    Alrasheed, Nouf
    Lee, Lydia
    Ghorani, Ehsan
    Henry, Jake Y.
    Conde, Lucia
    Chin, Melody
    Galas-Filipowicz, Daria
    Furness, Andrew J. S.
    Chavda, Selina J.
    Richards, Huw
    De-Silva, Dunnya
    Cohen, Oliver C.
    Patel, Dominic
    Brooks, Anthony
    Rodriguez-Justo, Manuel
    Pule, Martin
    Herrero, Javier
    Quezada, Sergio A.
    Yong, Kwee L.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3443 - 3454
  • [8] Increased marrow CD57+cytotoxic T cells is a powerful prognostic marker for survival in patients with relapsed multiple myeloma (MM) receiving thalidomide.
    Mileshkin, LR
    Gambell, P
    Beshay, V
    Hayakawa, Y
    Smyth, M
    Trivett, M
    Simmons, PJ
    Milner, A
    Zeldis, JB
    Prince, M
    BLOOD, 2005, 106 (11) : 973A - 973A
  • [9] Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients
    Nijhof, Inger S.
    de Weers, Michel
    Andre, Pascale
    van Kessel, Berris
    Lokhorst, Henk M.
    Parren, Paul W. H. I.
    Morel, Yannis
    Mutis, Tuna
    BLOOD, 2011, 118 (21) : 813 - 813
  • [10] The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
    Papatsirou, Maria
    Kontos, Christos K.
    Ntanasis-Stathopoulos, Ioannis
    Karousi, Paraskevi
    Malandrakis, Panagiotis
    Theodorakakou, Foteini
    Liacos, Christine Ivy
    Liosi, Aikaterini-Anna
    Kalioraki, Maria-Anna
    Mavrianou-Koutsoukou, Nefeli
    Fotiou, Despina
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    Scorilas, Andreas
    Terpos, Evangelos
    BLOOD, 2022, 140 : 7239 - 7240
12